Terms: = Breast cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
2396 results:
1. pDNA-tachyplesin treatment stimulates the immune system and increases the probability of apoptosis in MC4-L2 tumor cells.
Mahmoudi-Filabadi F; Doosti A
Amino Acids; 2024 May; 56(1):34. PubMed ID: 38691208
[TBL] [Abstract] [Full Text] [Related]
2. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic breast cancer Treated With Abemaciclib: Data From the SCRUM-Japan cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract] [Full Text] [Related]
5. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
6. Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.
Bahrin NWS; Matusin SNI; Mustapa A; Huat LZ; Perera S; Hamid MRWHA
Syst Rev; 2024 Apr; 13(1):100. PubMed ID: 38576013
[TBL] [Abstract] [Full Text] [Related]
7. Lapatinib antitumor effect is associated with pi3k and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
8. Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM; Han HS; Rugo HS; Stringer-Reasor EM; Specht JM; Dees EC; Kabos P; Suzuki S; Mutka SC; Sullivan BF; Gorbatchevsky I; Wesolowski R
Lancet Oncol; 2024 Apr; 25(4):474-487. PubMed ID: 38547892
[TBL] [Abstract] [Full Text] [Related]
9. Regulation of inflammatory response by LINC00346 via miR-25-3p-mediated modulation of the PTEN/pi3k/AKT/NF-κB pathway.
Kim MJ; Lim SG; Cho DH; Lee JY; Suk K; Lee WH
Biochem Biophys Res Commun; 2024 May; 709():149828. PubMed ID: 38537596
[TBL] [Abstract] [Full Text] [Related]
10. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic breast cancer Harboring Altered pi3k/AKT/mTOR.
Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
[TBL] [Abstract] [Full Text] [Related]
11. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (pi3k)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
12. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic breast cancer Patients.
Canino F; Tornincasa A; Bettelli S; Manfredini S; Barbolini M; Moscetti L; Omarini C; Toss A; Tamburrano F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473737
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
14. Dysregulated Gab1 signalling in triple negative breast cancer.
Bongartz H; Mehwald N; Seiß EA; Schumertl T; Naß N; Dittrich A
Cell Commun Signal; 2024 Mar; 22(1):161. PubMed ID: 38448989
[TBL] [Abstract] [Full Text] [Related]
15. EPAC inhibitor suppresses angiogenesis and tumor growth of triple-negative breast cancer.
Li Z; Liu Q; Cai Y; Ye N; He Z; Yao Y; Ding Y; Wang P; Qi C; Zheng L; Wang L; Zhou J; Zhang QQ
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167114. PubMed ID: 38447883
[TBL] [Abstract] [Full Text] [Related]
16. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Rodón J; Demanse D; Rugo HS; Burris HA; Simó R; Farooki A; Wellons MF; André F; Hu H; Vuina D; Quadt C; Juric D
Breast Cancer Res; 2024 Mar; 26(1):36. PubMed ID: 38439079
[TBL] [Abstract] [Full Text] [Related]
17. Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.
Huang ZH; Chen L; Sun Y; Liu Q; Hu P
J Transl Med; 2024 Mar; 22(1):226. PubMed ID: 38429796
[TBL] [Abstract] [Full Text] [Related]
18. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I; Romagnoli D; Galardi F; De Luca F; Biagioni C; Curigliano G; Criscitiello C; Minisini AM; Moretti E; Risi E; Guarducci C; Nardone A; Biganzoli L; Benelli M; Malorni L
JCO Precis Oncol; 2024 Feb; 8():e2300285. PubMed ID: 38427931
[TBL] [Abstract] [Full Text] [Related]
19. Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low breast cancer.
Han BY; Chen C; Luo H; Lin CJ; Han XC; Nasir J; Shi JX; Huang W; Shao ZM; Ling H; Hu X
Cancer Lett; 2024 Apr; 588():216763. PubMed ID: 38403109
[TBL] [Abstract] [Full Text] [Related]
20. Best of the year: Advanced breast cancer in 2023.
Schlam I; Chavez-MacGregor M
Breast; 2024 Apr; 74():103677. PubMed ID: 38401422
[TBL] [Abstract] [Full Text] [Related]
[Next]